Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

NCT02255097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: pembrolizumab

Sponsor

Merck Sharp & Dohme LLC